Sign inJoin waitlistJoin the waitlist

Kieron Dunleavy

Physician · MedStar Health

Credentials: · · · ·

History

MedStar Health
2026–Present

Hematology and Medical Oncology
1997–2000
Internal Medicine
1994–1997
Doctor of Medicine
1990–1994

Research

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour…
The Lancet Oncology · 2010 · 731 citations
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma
New England Journal of Medicine · 2013 · First of 13 authors · 434 citations
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Cancer Cell · 2017 · 425 citations

Wyndham Wilson
78 papers
Stefania Pittaluga
31 papers
Elaine Jaffe
28 papers
Mark Roschewski
20 papers
Richard Little
15 papers
CG
Cliona Grant
11 papers · 8 as a resident
Christopher Melani
9 papers · 4 as a fellow
AN
Ariela Noy
8 papers
Catherine Lai
8 papers · 4 as a fellow
JJ
John Janik
7 papers
MS
Maryalice Stetler-Stevenson
7 papers
Mark Raffeld
6 papers

Clinical trials

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Principal investigator · Active not recruiting · Phase 2
Georgetown University
2018–2026
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2014–2027